

Antitumor Effect of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies plus *cis*-Diamminedichloroplatinum on Well Established A431 Cell Xenografts¹

Zhen Fan, Jose Baselga, Hideo Masui, and John Mendelsohn²

Laboratory of Receptor Biology, Memorial Sloan-Kettering Cancer Center [Z. F., J. B., H. M., J. M.] and Cornell University Medical School [J. M.], New York, New York 10021

ABSTRACT

We have explored the therapeutic effects of anti-epidermal growth factor receptor monoclonal antibodies (MAbs) 225 and 528 on well established A431 epidermoid carcinoma xenografts, approximately 400 mm³ (1 cm in diameter) at the start of treatment. In previous reports we demonstrated that MAbs 225 and 528 prevented the growth of A431 cell xenografts in nude mice when treatment was begun on the day of tumor cell inoculation. Since anti-epidermal growth factor receptor MAb therapy of well established tumors was unable to retard growth, we explored combination therapy with MAb plus the chemotherapeutic agent *cis*-diamminedichloroplatinum (*cis*-DDP). Additive and concentration-dependent growth-inhibitory effects of MAb with *cis*-DDP were observed in cultures of A431 cells. Neither intensive treatment with 225 MAb (1 mg/mouse, i.p. on day 8 after tumor inoculation, and twice weekly for 4 weeks) nor a maximally tolerated single dose of *cis*-DDP [150 µg/25 g (6 mg/kg) mouse weight, i.p. on day 8] had significant effects on tumor growth. However, the two treatments in combination resulted in substantial xenograft growth inhibition, compared with both an untreated control group and animals treated with a single modality. When a second dose of *cis*-DDP (150 µg/25 g) was added after 10 days, combination therapy with 225 MAb produced striking antitumor effects. At the end of 1 month tumor xenografts had disappeared in all but one mouse, and no tumor relapses occurred during 6 months of observation. Identical results were obtained with anti-epidermal growth factor receptor MAb 528 in combination with *cis*-DDP. The results of these studies provide a novel approach to the treatment of well established tumor xenografts, which may have application in the therapy of human malignancies.

INTRODUCTION

High expression of EGF³ receptors and the presence of a potential TGF- α mediated autocrine stimulation pathway in many human cancers have stimulated investigation of therapy with MAbs that block binding of ligand to EGF receptors (1–10). We have produced and characterized two MAbs against the EGF receptor, 225 IgG₁ and 528 IgG_{2a}, which bind to the receptor with affinity similar to EGF and TGF- α , compete with these ligands for receptor binding, and block EGF or TGF- α induced activation of EGF receptor tyrosine phosphorylation (11–14). These MAbs inhibit proliferation of a variety of cultured malignant human cell lines which express EGF receptors and TGF- α , including vulva (11–13), breast (15, 16), colon (17, 18), lung (19), renal (20), and prostate cancers (21). MAb 455, which binds to EGF receptors without inhibiting the binding of ligand, had no effect on proliferation of cultured cell lines (11, 22).

Additional experiments demonstrated the capacity of these anti-EGF receptor MAbs to produce concentration-dependent inhibition of xenografts of human tumor cell lines, which appeared to depend upon

autocrine EGF receptor stimulation for growth in culture. A dose of 1 mg 225 or 528 MAb twice weekly, by i.p. injection, could sustain serum levels adequate to saturate EGF receptors (23). Anti-EGF receptor MAb therapy successfully inhibited the growth of xenografted tumor cell lines from squamous cancers of the vulva and lung, as well as adenocarcinomas of the breast and colon (18, 19, 23–27). Inhibitory activity against xenografts was also observed with the F(ab')₂ fragment of 225 MAb, indicating that pharmacological blockade of EGF receptor by antibody without the capacity for an immune response can also mediate the antitumor effect *in vivo* (28). In these studies, treatment with MAb was begun the day of tumor cell inoculation.

To initiate investigation of the clinical application of our anti-EGF receptor MAbs, we performed a phase I clinical trial of a single dose of ¹¹¹In-labeled 225 MAb (29). At MAb doses of 40 mg or higher, imaging studies on patients with advanced squamous cell carcinoma of the lung visualized each primary tumor and presumed sites of metastatic disease with diameter >1 cm. The serum concentration of 225 MAb could be maintained at >40 nM (receptor saturating levels) for more than 3 days without toxicity. Collectively, these preclinical and early clinical studies make a strong case for exploring the potential therapeutic role of anti-EGF receptor MAbs as pharmacological agents that block tyrosine kinase mediated signal transduction.

The premise for our approach is that anti-EGF receptor MAbs block the access of EGF or TGF- α to their receptors, resulting in the inhibition of tumor growth. Studies with cell cultures suggest that blockade of EGF receptors by MAbs results primarily in cytostatic rather than cytotoxic effects (11–14). Furthermore, treatment with MAb has not successfully eliminated well established xenografts (23). An exception is the DiFi colon adenocarcinoma cell line which is extremely sensitive to MAb treatment, both in culture and in xenografts (18). Therefore, for the treatment of most well established tumors, it was important to explore methods for enhancing the antitumor effects of anti-EGF receptor MAbs.

There has been interest in combining cytotoxic chemotherapeutic agents with growth-inhibitory biological agents, including MAbs against the EGF receptor (30, 31) and against HER2/*c-erbB-2* protein (p185^{HER2}) (32, 33). There is an excellent rationale for exploring these combinations. The antiproliferative effect of MAbs targeted against receptors on plasma membranes may be limited by competition with growth factors produced and released in the cellular environment. Chemotherapy can act to reduce the number of malignant cells, thereby reducing the concentration of essential autocrine growth factors produced in the immediate environment of residual viable cells. The potential of cell membrane receptors and signal transduction pathways to serve as opportune targets for cancer chemotherapy also has received considerable attention (34, 35). Furthermore, recent studies indicate that both chemotherapy-induced cytotoxicity and death of cells deprived of essential growth factors may involve programmed cell death or apoptosis (36–39), suggesting a common cytotoxic pathway that might be augmented by combination therapy.

cis-DDP is an alkylating agent which produces interstrand and intrastrand base cross-linking in DNA and is one of the most active drugs against the human epithelial tumors that express high levels of

Received 6/10/93; accepted 8/19/93.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹This work was supported by The Dror Friedenbergs Foundation and NIH Grants CA42060 and CA37641.

²To whom requests for reprints should be addressed, at Box 156, 1275 York Avenue, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

³The abbreviations used are: EGF, epidermal growth factor; TGF- α , transforming growth factor α ; MAb, monoclonal antibody; *cis*-DDP, *cis*-diamminedichloroplatinum.

EGF receptors (40). The purpose of the present study was to determine whether the antitumor effect of anti-EGF receptor MAb against well established A431 cell xenografts can be enhanced by combination treatment with *cis*-DDP.

MATERIALS AND METHODS

Materials. Human epidermoid carcinoma cell line A431 and anti-EGF receptor MAbs 225, 528, and 455 have been previously described (11, 12). BALB/c nude mice used in this study were bred and maintained in the animal facility at Memorial Sloan-Kettering Cancer Center as previously described (41). *cis*-DDP (platinol) was a gift from the Bristol Myers-Squibb Company.

Cell Culture and Growth Assay. A431 cells were maintained in 1:1 Dulbecco's modified Eagles's medium/Ham's F-12 mixture (v/v) supplemented with 10% fetal calf serum. Cells were distributed into 6-well plates, and treatment was started the next day. *cis*-DDP was freshly dissolved in phosphate-buffered saline and added to appropriate wells, with or without anti-EGF receptor MAb at concentrations indicated in the figure legends. After 24 h, the drug was removed by washing the cells twice, followed by addition of cell culture medium and MAb. The medium and MAb were replenished every 2–3 days. After 6 days of culture, cells were harvested by trypsinization and counted with a Coulter counter.

A431 Cell Xenografts. BALB/c nude mice were implanted s.c. with 10^7 A431 cells/mouse. Tumors were measured every 3–4 days with vernier calipers. Tumor size was calculated by the formula:

$$\frac{\pi}{6} ab^2$$

where a is the length and b is the width, and $a \geq b$. Animals with established tumor xenografts were divided into groups with comparable tumor size and treated, as described in the text and figure legends. Briefly, for anti-EGF receptor MAb treatment, mice received 1 mg of MAb *i.p.* in phosphate-buffered saline twice a week, starting on day 3, 5, or 8 after tumor cell inoculation and ending on day 32. Previous studies have established this as the dose of MAb required for prevention of tumor growth (23). Various doses and schedules of *i.p.* *cis*-DDP were explored in tumor-bearing nude mice, beginning 8 days after tumor cell inoculation. The mice were followed for the observation of xenograft growth rate, body weight changes, and life span.

RESULTS

Effects of Anti-EGF Receptor MAb 225 upon Well Established Tumor Xenografts. The data in Fig. 1 show that inhibition of A431 cell xenografts by 225 MAb is dependent upon tumor size. We demonstrated previously that anti-EGF receptor MAbs 225 and 528 prevented the formation of s.c. tumor xenografts when the nude mice were treated with 1 mg MAb *i.p.* beginning on the day of tumor cell inoculation and that treatment with an irrelevant IgG antibody had no inhibitory effect (23, 24). Treatment of nude mice with 225 MAb beginning 3 days after tumor cell inoculation, when the mean tumor size was about 150 mm^3 , also was able to inhibit the formation of A431 cell xenografts (Fig. 1). However, if MAb treatment was delayed until 5 days after tumor cell inoculation, when tumors reached a mean size of about 200 mm^3 , 225 MAb could only retard tumor xenograft growth. If the treatment was started 8 days after tumor cell inoculation, when the tumor was well established with a mean size of about 400 mm^3 (approximately 1 cm in diameter), 225 MAb had almost no effect on xenograft growth. The experiment in Fig. 1 is representative of three independent studies showing limited response to MAb therapy at this and higher doses. Similar results also were observed with 528 MAb treatment (data not shown).

Additive Cytotoxicity of *cis*-DDP and Anti-EGF Receptor MAb in Cell Culture. Experiments were carried out to determine the effect of *cis*-DDP at subtoxic dose, both alone and combined with 225 or 528 MAb, on the growth of A431 cell cultures. Fig. 2A shows the response to increasing concentrations *cis*-DDP. To more closely mimic *in vivo*




Fig. 1. The inhibition of A431 cell xenografts by anti-EGF receptor MAb 225 is dependent upon tumor size. MAb 225 treatment (1 mg/mouse, *i.p.*, twice a week) was started on day 3 (■), 5 (▼), or 8 (▲) after s.c. tumor inoculation and ended on day 32 (arrows). The control group was treated with phosphate-buffered saline (●). The data are expressed as the mean tumor size \pm SE (7 mice per group).




Fig. 2. Additive cytotoxicity of *cis*-DDP in combination with 225 MAb on A431 cell cultures. A431 cells were seeded onto 6 well plates at 2×10^4 cells/well. In A, A431 cells were treated with *cis*-DDP at indicated concentrations on the first day for a total of 24 h, in the continuous presence (▨) or absence (■) of 20 nM 225 MAb for 6 days. In B, A431 cells were treated with indicated concentrations of 225 MAb for 6 days, plus (▨) or minus (■) 0.1 $\mu\text{g/ml}$ (0.33 μM) *cis*-DDP during the first day only. The data are presented as the mean cell number of triplicates with SE bars.

treatment conditions, the exposure time of A431 cells to *cis*-DDP was only for the first 24 h, and the cells were maintained in culture for an additional 5 days after removal of the drug. *cis*-DDP inhibited A431 cell proliferation in a dose-dependent fashion. The continuous presence of 20 nM 225 MAb (a saturating concentration) for 6 days produced additive inhibitory effects on cell growth. Conversely, this additive effect was also observed when the concentration of 225 MAb varied from 0.2 to 200 nM, in cultures treated for 24 h with 0.1 $\mu\text{g/ml}$ (0.33 μM) *cis*-DDP (Fig. 2B). Identical results were obtained when 225 MAb was replaced by 528 MAb, which also blocks binding of EGF/TGF- α ; however, no additive effect was found when 225 MAb was replaced by 455 MAb, which binds to EGF receptors but does not block binding of EGF/TGF- α (data not shown).

Toxicity and Antitumor Activity of *cis*-DDP on Xenografted Nude Mice. In preliminary studies, we found that nude mice bearing tumor xenografts were more vulnerable to toxicity from chemotherapy than non-tumor-bearing mice. Therefore, we explored the dose of

cis-DDP tolerated by nude mice bearing well established A431 cell xenografts. On the basis of the pilot data, a dose of *cis*-DDP at either 100 or 300 $\mu\text{g}/25\text{ g}$ (4 or 12 mg/kg) mouse weight was selected for i.p. administration on day 8 after A431 cell inoculation. Fig. 3 presents the dose-dependent toxicity of *cis*-DDP on the xenografted nude mice. Mice receiving the higher dose (300 $\mu\text{g}/25\text{ g}$) of *cis*-DDP lost 10–15% of body weight and reduced their physical activities 1 week after chemotherapy, and all of these animals died within 44 days (Fig. 3B), in spite of a marked reduction in xenograft growth rate (Fig. 3A). The deaths observed in this higher *cis*-DDP dose group were attributed primarily to toxicity from *cis*-DDP. Treatment with the lower dose (100 $\mu\text{g}/25\text{ g}$) of *cis*-DDP had little effect on the size of the xenografts, and there was no detectable toxicity on the nude mice. Therefore, the deaths of mice treated with the lower dose of *cis*-DDP were mainly attributed to the tumor burden, as with the control mice (Fig. 3, A and B).

Combination Treatment of Xenografts with *cis*-DDP and Anti-EGF Receptor MAb. To explore whether *cis*-DDP could augment the weak antiproliferative effect of MAb against well-established A431 cell xenografts, combination treatment with *cis*-DDP and 225 MAb was administered. The therapy was started 8 days after A431 cells were inoculated and had reached a mean size of approximately 400 mm^3 (1 cm in diameter). Based on the results of the toxicity studies, a single *cis*-DDP dose at 150 $\mu\text{g}/25\text{ g}$ (6 mg/kg) mouse weight was administered. To examine other possible drug schedules, we also explored splitting the single *cis*-DDP dose (150 $\mu\text{g}/25\text{ g}$) into three injections of 50 $\mu\text{g}/25\text{ g}$ at 1-week intervals in the same experiment. Fig. 4 shows the results of these experiments. As expected, 225 MAb (1 mg/mouse, twice weekly for 4 weeks) was unable to inhibit A431 cell xenograft growth. The single dose of *cis*-DDP (150 $\mu\text{g}/25\text{ g}$) on day 8 had a modest effect initially, but the tumors started to grow as rapidly as controls after day 15. However, xenograft growth was significantly inhibited by the combination of *cis*-DDP plus MAb treatment: the tumors remained at their initial size until day 22 and then began to resume growth at a reduced rate (Fig. 4A). The parallel study in Fig. 4B shows that the split dose of *cis*-DDP (50 $\mu\text{g}/25\text{ g}$) given every 7 days produced inhibition of xenograft growth that may have been modestly more effective than the single higher dose of *cis*-DDP (150 $\mu\text{g}/25\text{ g}$), with no significant change in the response to combination therapy.

For optimal combination therapy, these results suggest that a maximally tolerated dose of *cis*-DDP should be administered initially and that multiple doses of *cis*-DDP might be required. Therefore, an experimental protocol was designed to administer a second full dose of *cis*-DDP 10 days after the initial dose of *cis*-DDP (150 $\mu\text{g}/25\text{ g}$), when it could be tolerated. A striking antitumor response was observed. In

the experiment shown in Fig. 5, the growth of A431 cell xenografts was completely suppressed, and the tumors gradually shrank. By day 32, after 8 injections of 225 MAb and two treatments with *cis*-DDP, tumors had been eliminated in 6 out of 7 treated mice. One mouse had a residual tumor less than 100 mm^3 . All of the mice in the 225 MAb alone, *cis*-DDP alone and control groups died or had to be sacrificed due to bulky tumor burdens. However, in the combination treatment group, mice with regressed tumors were observed for over 6 months and remained tumor-free. The single mouse treated with combination therapy which had a residual tumor lump also survived for over 6 months with a slowly growing tumor. These results were duplicated in subsequent experiments.

The treatment protocol in Fig. 5 was repeated using anti-EGF receptor MAb 528, which shares many properties with 225 MAb except that they differ in their IgG isotype. Fig. 6 shows the results obtained with combination therapy. There was complete tumor regression in each of the 7 mice in the 528 MAb plus *cis*-DDP combination treatment group, and these mice remained tumor free for over 6 months.

DISCUSSION

The present studies demonstrate curative therapy of well established tumor xenografts (approximately 400 mm^3) by treatment with an anti-EGF receptor MAb. This required combination therapy with the chemotherapeutic agent, *cis*-DDP. Successful tumor eradication depended upon preliminary experiments to determine maximum tolerated doses of chemotherapy (Fig. 3) as well as optimal dose and scheduling of MAb (23). Most importantly, we treated under conditions in which either MAb alone or *cis*-DDP alone had almost no capacity to inhibit tumor xenograft growth, thereby establishing that strong antitumor interactions result from combination therapy. We also have observed similar results with another drug, Adriamycin (31).

Combination treatment with anti-EGF receptor MAb 108 IgG_{2a} plus a single dose of *cis*-DDP has been shown previously to prevent the formation of human epidermoid carcinoma KB cell xenografts (30). Treatment of these xenografts was performed only 1 day after tumor cell inoculation. Another study examined treatment with anti-p185^{HER2} MAb TAB 250 in combination with *cis*-DDP against human SKOV3 ovarian tumor xenografts (32). Combination therapy resulted in the elimination of tumor xenografts less than 50 mm^3 in size, but for larger tumors (150–200 mm^3) this response to combined therapy was not observed.

We have demonstrated that A431 cell proliferation in culture is dependent upon autocrine stimulation of EGF receptors by growth factor (11–14, 42). What are the explanations for the apparent resis-





Fig. 3. Toxicity and antitumor activity of *cis*-DDP on nude mice bearing A431 cell xenografts. A431 cells (10^7) were implanted s.c. into nude mice and allowed to grow for 8 days. Mice were given i.p. injections with a single dose of *cis*-DDP at either 100 μg (\blacktriangle) or 300 μg (\blacktriangledown)/25 g mouse weight (arrow). The control group was treated with phosphate-buffered saline (\bullet). Mice were observed for tumor growth (A) as well as their life span (B). The data are expressed as the mean tumor size \pm SE (5–6 mice/group). Plots of tumor size after day 24 of the experiment are not shown because of the statistical invalidity with three or fewer mice.

Fig. 4. Antitumor effect of anti-EGF receptor MAb 225 in combination with *cis*-DDP. In A, A431 cells (10^7) were implanted s.c. into nude mice and allowed to grow for 8 days. The mice were then given i.p. injections of either phosphate-buffered saline (●); 150 μ g *cis*-DDP/25 g mouse weight (▲); or 225 MAb, 1 mg/mouse, twice a week for 4 weeks, with (■) or without (▼) 150 μ g *cis*-DDP/25 g mouse weight on day 8. Arrows, the timing of drug and antibody treatment. In B, the *cis*-DDP dose used in A was split into three parts (50 μ g *cis*-DDP/25 g mouse weight), given i.p. over 3 successive weekly intervals (arrows). The data are expressed as the mean tumor size \pm SE (8–12 mice per group).



tance to MAb-mediated EGF receptor blockade when A431 cell xenografts become well established? First, we have observed that the inhibition of A431 cell proliferation by MAb was more prominent in low cell density cultures than in high cell density cultures (data not shown). A similar observation was also made with our anti-EGF receptor MABs in cultures of colon and breast cells (22, 43). It was suggested that this may be attributed to low local concentrations of autocrine-derived TGF- α in the low density cell cultures, creating enhanced vulnerability to EGF receptor blockade by MAb. A comparable situation may occur when small numbers of tumor cells are injected into nude mice, because low concentrations of autocrine-derived TGF- α would be produced at the local site. Since administration of exogenous EGF stimulates the growth of A431 cell xenografts in nude mice (44), it is likely that autocrine-derived levels of TGF- α are less than optimal for A431 cell growth *in vivo*, and the local concentration of growth factor could be rate limiting when there are small numbers of tumor cells.

Second, the poor antitumor response to treatment of well established A431 cell xenografts with anti-EGF receptor MAB might be due to inadequate delivery of MAB to the tumor because of limiting blood supply or poor diffusion into tumor tissues. However, two lines of evidence suggest otherwise. We have examined the localization of anti-EGF receptor MAB in A431 cell xenografts after 2 weeks of therapy and find it well distributed in central portions of the tumor (data not shown). Furthermore, while A431 cell xenografts are resistant to MAb 225 therapy initiated on day 8, well established xenografts of other tumor cells can respond to anti-EGF receptor MAB treatment by arresting growth (23), or, in the case of DiFi cells, by

undergoing total regression (18). These observations suggest that individual characteristics of particular tumor cells may account, in part, for the response to delayed initiation of anti-EGF receptor MAB therapy.

The mechanism(s) accounting for enhanced antitumor effects by combination treatment with anti-EGF receptor MAB and *cis*-DDP are under exploration. We have considered a number of possibilities. It is possible that two methods for inhibiting cell growth have produced additive effects by two independent pathways, and the apparent additive effects of anti-receptor MAB and *cis*-DDP in cell culture would support this explanation. However, the combination of MAB and *cis*-DDP clearly produced a dose- and schedule-dependent antitumor activity that was more than additive in the *in vivo* situation: under conditions in which single agent therapy had little effect, combined treatment completely eradicated well established tumors. The factors relating to increased efficacy of MAB-mediated receptor blockade when the tumor burden is small (see above), suggest that cytoreduction produced by *cis*-DDP could greatly enhance the antitumor activity of MAB. In our xenograft experiments, treatment with *cis*-DDP alone did not reduce the tumor burden to levels which were shown to respond to MAB alone. However, it is possible that a modest cytotoxic effect of chemotherapy caused changes in the microenvironment (e.g., increased vascular permeability) that could enhance the capacity of MAB to reach tumor cells.

It is interesting to speculate that the mechanism of cell death resulting from combined therapy involves a common pathway. Damage to cellular DNA by agents such as *cis*-DDP is followed by arrest of cell cycle traversal accompanied by active DNA repair. If this is

Fig. 5. Eradication of A431 cell xenografts by combination treatment with 225 MAB and *cis*-DDP. A431 cells (10^7) were implanted s.c. into nude mice and allowed to grow for 8 days. In A, the mice were given i.p. injections of either phosphate-buffered saline (●); two injections of *cis*-DDP (150 μ g/25 g mouse weight) on day 8 and day 18 (▲); or 225 MAB, 1 mg/mouse, twice a week for 4 weeks, with (■) or without (▼) two injections of *cis*-DDP (150 μ g/25 g mouse weight) on day 8 and day 18. Arrows, the timing of drug and antibody treatment. The data are expressed as the mean tumor size \pm SE (7 mice per group). In B, the mice were observed for 6 months for survival.





Fig. 6. Eradication of A431 cell xenografts by combination treatment of 528 MAb and *cis*-DDP. The 225 MAb in Fig. 5 treatment protocol was replaced by 528 MAb. In A, A431 cell xenografts were treated as in Fig. 5. The data are expressed as the mean tumor size \pm SE (7 mice per group). In B, the mice were observed for 6 months for survival.



unsatisfactory, programmed cell death is activated, leading to apoptosis (36–39). Cells deprived of essential growth factors also arrest cell cycle traversal, typically at a restriction point in G_1 phase, and there is evidence that malignant cell cultures have reduced capacity to growth arrest when deprived of serum or growth factors (45). Recent studies have demonstrated that when some hematopoietic cell lines are deprived of essential growth factors they undergo apoptosis in cell culture (39). These observations suggest that the interactions of *cis*-DDP chemotherapy and EGF receptor blockade may have induced cell death by acting upon common biochemical pathways involving apoptosis.

Reduction in protein phosphorylation that results from blockade of EGF receptor-mediated kinase activity might also explain the efficacy of combination therapy. The possible roles of phosphorylation via this signal transduction pathway upon uptake of *cis*-DDP and upon repair of *cis*-DDP-mediated DNA damage are presently under exploration. The biochemical pathways that mediate cell cycle arrest are known to involve phosphorylation of a number of key mediators including, for example, *p53* and *cdc2* kinase. These phosphorylations are many steps removed from EGF receptor activation but might be influenced by blockade of receptor kinase activity.

Experiments are underway testing these possible mechanisms. We have demonstrated previously that treatment with a nonspecific polyclonal murine IgG can not substitute for anti-EGF receptor MAbs in inhibiting the growth of xenografts alone (23) or combined with chemotherapeutic agent, doxorubicin (31). In addition, others have demonstrated that treatment of human tumor xenografts with tumor-reactive IgG_{2a} MAb plus doxorubicin did not enhance the antitumor activity of chemotherapy alone (46). However, the possibility still needs to be considered that immune mechanisms activated by the Fc portion of anti-EGF receptor MAb could be contributing to the cytotoxicity induced by combination therapy in the present experiments.

In conclusion, these studies are the first to present evidence that when blockade of the EGF receptor signal transduction pathway by MAbs is combined with *cis*-DDP chemotherapy, well established tumor xenografts can be successfully eliminated. Based on these observations, clinical trials of combination therapy with human chimerized MAb 225 plus *cis*-DDP chemotherapy will be carried out. This may be a novel form of therapy for the many types of human tumors which appear to depend upon EGF receptor stimulation for proliferation (11–21).

ACKNOWLEDGMENTS

The collaboration of Dr. Larry Norton in designing the treatment protocols used in these studies is gratefully acknowledged.

REFERENCES

- Ozanne, B., Richards, C. S., Hendler, F., Burns, D., and Gusterson, B. Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas. *J. Pathol.*, **149**: 9–14, 1986.
- Sobol, R. E., Astarita, R. W., Hofedits, C., Masui, H., Fairshter, R., Royston, I., and Mendelsohn, J. Epidermal growth factor expression in human lung carcinoma defined by a monoclonal antibody. *J. Natl. Cancer Inst.*, **79**: 403–407, 1987.
- Veale, D., Kerr, N., Gibson, G. H., and Harris, A. L. Characterization of epidermal growth factor receptor in primary human non-small cell lung cancer. *Cancer Res.*, **49**: 1313–1317, 1989.
- Libermann, T. A., Razon, N., Bartal, A. D., Yarden, Y., Schlessinger, J., and Soreq, H. Expression of epidermal growth factor receptors in human brain tumors. *Cancer Res.*, **44**: 753–760, 1984.
- Harris, A. L., Nicholson, S., Sainsbury, J. R. C., Neal, D., Smith, K., Farndon, J. R., and Wright, C. Epidermal growth factor receptors: a marker of early relapse in breast cancer and tumor stage progression in bladder cancer; interactions with *neu*. In: M. Furth and M. Greaves (eds.), *The Molecular Diagnostics of Human Cancer*. Vol. 7, pp. 353–357. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
- Sainsbury, J. R. C., Malcolm, A. J., Appleton, D. R., Farndon, J. R., and Harris, A. L. Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. *J. Clin. Pathol.*, **38**: 1225–1228, 1985.
- Eisbruch, A., Blick, M., Lee, J. S., Sacks, P. G., and Gutterman, J. Analysis of the epidermal growth factor receptor gene in fresh human head and neck tumors. *Cancer Res.*, **47**: 3603–3605, 1987.
- Neal, D. E., Bennett, M. K., Hall, R. R., March, C., Abel, P. D., Sainsbury, J. R. C., and Harris, A. L. Epidermal growth factor receptors in human bladder cancer: comparison of invasive and superficial tumors. *Lancet*, **1**: 366–368, 1985.
- Hendler, F., Shum-Siu, A., Nanu, L., Yuan, D., and Ozanne, B. Increased EGF receptors and absence of an alveolar differentiation marker predict a poor survival in lung cancer (Abstract 869). *Proc. Am. Soc. Clin. Oncol.*, **8**: 223, 1989.
- Veale, D., Ashcroft, T., Marsh, C., Gibson, G. J., and Harris, A. L. Epidermal growth factor receptors in non-small cell lung cancer. *Br. J. Cancer*, **55**: 513–516, 1987.
- Sato, J. D., Kawamoto, T., Le, A. D., Mendelsohn, J., Polikoff, J., and Sato, G. H. Biological effect *in vitro* of monoclonal antibodies to human EGF receptors. *Mol. Biol. Med.*, **1**: 511–529, 1983.
- Kawamoto, T., Sato, J. D., Le, A., Polikoff, J., Sato, G. H., and Mendelsohn, J. Growth stimulation of A431 cells by EGF: identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. *Proc. Natl. Acad. Sci. USA*, **80**: 1337–1341, 1983.
- Kawamoto, T., Mendelsohn, J., Le, A., Sato, G., Lazar, C. S., and Gill, G. N. Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells. *J. Biol. Chem.*, **259**: 7761–7766, 1984.
- Gill, G. N., Kawamoto, T., Cochet, C., Le, A., Sato, J. D., Masui, H., MacLeod, C. L., and Mendelsohn, J. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. *J. Biol. Chem.*, **259**: 7755–7760, 1984.
- Arteaga, C. L., Coronado, E., and Osborne, C. K. Blockade of the epidermal growth factor receptor inhibits transforming growth factor- α -induced but not estrogen-induced growth of hormone-dependent human breast cancer. *Mol. Endocrinol.*, **2**: 1064–1069, 1988.
- Ennis, B. W., Valverius, E. M., Lippman, M. E., Bellot, F., Kris, R., Schlessinger, J., Masui, H., Goldenberg, A., Mendelsohn, J., and Dickson, R. B. Monoclonal anti-EGF receptor antibodies inhibit the growth of malignant and non-malignant human mammary epithelial cells. *Mol. Endocrinol.*, **3**: 1830–1838, 1989.
- Karnes, W. E., Jr., Walsh, J. H., Wu, S. V., Kim, R. S., Martin, M. G., Wong, H. C., Mendelsohn, J., Gazdar, A. F., and Cuttitta, F. Autocrine stimulation of EGF receptors by TGF- α regulates autonomous proliferation of human colon cancer cells. *Gastroenterology*, **102**: 474–485, 1992.
- Masui, H., Boman, B., Hyman, J., Castro, L., and Mendelsohn, J. Treatment with anti-EGF receptor monoclonal antibody causes regression of DiFi human colorectal carcinoma xenografts (Abstract 2340). *Proc. Am. Assoc. Cancer Res.*, **32**: 394, 1991.

19. Reiss, M., Stash, E. B., Vellucci, V. F., and Zhou, Z-I. Activation of the autocrine transforming growth factor α pathway in human squamous carcinoma cells. *Cancer Res.*, 51: 6254-6262, 1992.
20. Atlas, I., Mendelsohn, J., Baselga, J., Masui, H., Fair, W. R., and Kumar, R. Growth regulation of human renal carcinoma cells: role of transforming growth factor- α . *Cancer Res.*, 52: 3335-3339, 1992.
21. Hofer, D. R., Sherwood, E. R., Bromberg, W. D., Mendelsohn, J., Lee, C., and Kozlowski, J. M. Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor- α . *Cancer Res.*, 51: 2780-2785, 1991.
22. Markowitz, S. D., Molkentin, K., Gerbic, C., Jackson, J., Stellato, T., and Willson, J. K. V. Growth stimulation by coexpression of transforming growth factor- α and epidermal growth factor-receptor in normal and adenomatous human colon epithelium. *J. Clin. Invest.*, 6: 356-362, 1990.
23. Masui, H., Kawamoto, T., Sato, J. D., Wolf, B., Sato, G. H., and Mendelsohn, J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. *Cancer Res.*, 44: 1002-1007, 1984.
24. Masui, H., Moroyama, T., and Mendelsohn, J. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotype. *Cancer Res.*, 46: 5592-5598, 1986.
25. Mendelsohn, J., Masui, H., and Goldenberg, A. Anti-epidermal growth factor receptor monoclonal antibodies may inhibit A431 tumor cell proliferation by blocking an autocrine pathway. *Trans. Assoc. Am. Phys.*, 100: 173-178, 1987.
26. Mendelsohn, J. Potential clinical application of anti-EGF receptor monoclonal antibodies. *In: M. Furth and M. Greaves (eds.), The Molecular Diagnostics of Human Cancer, Vol. 7, pp. 359-362. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.*
27. Goldenberg, A., Masui, H., Divgi, C., Kamrath, H., Pentlow, K., and Mendelsohn, J. Imaging of human tumor xenografts with an indian-111 labeled anti-epidermal growth factor receptor monoclonal antibody. *J. Natl. Cancer Inst.*, 81: 1616-1625, 1989.
28. Fan, Z., Masui, H., Atlas, I., and Mendelsohn, J. Blockade of epidermal growth factor receptor function by both bivalent and monovalent fragment of 225 anti-EGF receptor monoclonal antibodies. *Cancer Res.*, 53: 4322-4328, 1993.
29. Divgi, C. R., Welt, C., Kris, M., Real, F. X., Yeh, S. D. J., Gralla, R., Merchant, B., Schweighart, S., Unger, M., Larson, S. M., and Mendelsohn, J. Phase I and imaging trial of indian-111 labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. *J. Natl. Cancer Inst.*, 83: 97-104, 1991.
30. Aboud-Pirak, E., Hurwitz, E., Pirak, M. E., Bellot, F., Schlessinger, J., and Sela, M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma *in vitro* and in nude mice. *J. Natl. Cancer Inst.*, 80: 1605-1611, 1988.
31. Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W. H., and Mendelsohn, J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. *J. Natl. Cancer Inst.* 85: 1327-1333, 1993.
32. Hancock, M. C., Langton, B. C., Chan, T., Toy, P., Monahan, J. J., Mischak, R. P., and Shawver, L. K. A monoclonal antibody against the *c-erbB-2* protein enhances the cytotoxicity of *cis*-diamminedichloroplatinum against human breast and ovarian tumor cell lines. *Cancer Res.*, 51: 4575-4580, 1991.
33. Pegram, M. D., Pietras, R. J., and Slamon, D. J. Monoclonal antibody to *HER-2/neu* gene product potentiates cytotoxicity of carboplatin and doxorubicin in human breast tumor cells (Abstract 2639). *Proc. Am. Assoc. Cancer Res.*, 33: 442, 1992.
34. Tritton, T. R., and Hickman, J. A. How to kill cancer cells: membranes and cell signaling as targets in cancer chemotherapy. *Cancer Cells*, 2: 95-105, 1990.
35. Tritton, T. R. Cell surface actions of Adriamycin. *Pharmacol. Ther.*, 49: 293-309, 1991.
36. Marks, D. I., and Fox, R. M. DNA damage, poly(ADP-ribosyl)ation and apoptotic cell death as a potential common pathway of cytotoxic drug action. *Biochem. Pharmacol.*, 42: 1859-1867, 1991.
37. Barry, M. A., Behnke, C. A., and Eastman, A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drug, toxins and hyperthermia. *Biochem. Pharmacol.*, 40: 2353-2362, 1990.
38. Dive, C., and Hickman, J. A. Drug-target interactions: only the first step in the commitment to a programmed cell death? *Br. J. Cancer*, 64: 192-196, 1991.
39. Williams, G. T., Smith, C. A., Spooncer, E., Dexter, T. M., and Taylor, D. R. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. *Nature (Lond.)*, 343: 76-79, 1990.
40. Andrews, P. A., and Howell S. B. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. *Cancer Cells*, 2: 35-43, 1990.
41. Reig, L., Colburn, P., Sato, G., and Kaplan, N. O. Approaches to chemotherapy using the athymic nude mice. *In: D. P. Houchens and A. A. Ovejera (eds.), Proceedings of the Symposium on the Use of Athymic (Nude) Mice in Cancer Research, pp. 123-131. New York: Gustav Fischer, 1978.*
42. Van de Vijver, M., Kumar, R., and Mendelsohn, J. Ligand-induced activation of A431 cell EGF receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly. *J. Biol. Chem.*, 266: 7503-7508, 1991.
43. Bates, S. E., Valverius, E. M., Ennis, B. W., Bronzert, D. A., Sheridan, J. P., Stampfer, M. R., Mendelsohn, J., Lippman, M. E., and Dickson, R. B. Expression of the TGF- α /EGF receptor pathway in normal human breast epithelial cells. *Endocrinol.*, 126: 596-607, 1990.
44. Ginsburg, E., and Vonderhaar, B. K. Epidermal growth factors stimulates the growth of A431 tumors in athymic mice. *Cancer Lett.*, 28: 143-150, 1985.
45. Pardee, A. B., Dubrow, R., Hamlin, J. L., and Kletzien, R. F. Animal cell cycle. *Annu. Rev. Biochem.*, 47: 715-750, 1978.
46. Yang, H. M., and Reisfeld, R. A. Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. *Proc. Natl. Acad. Sci. USA*, 85: 1189-1193, 1988.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

Antitumor Effect of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies plus *cis*-Diamminedichloroplatinum on Well Established A431 Cell Xenografts

Zhen Fan, Jose Baselga, Hideo Masui, et al.

Cancer Res 1993;53:4637-4642.

Updated version Access the most recent version of this article at:
<http://cancerres.aacrjournals.org/content/53/19/4637>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://cancerres.aacrjournals.org/content/53/19/4637>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.